Clinical Experience With Gene Therapy in Older Patients With Spinal Muscular Atrophy.

Autor: Matesanz SE; Division of Neurology, Children's Hospital of Philadelphia, University of Pennsylvania the Perelman School of Medicine, Philadelphia, Pennsylvania. Electronic address: matesanzs@email.chop.edu., Battista V; Division of Neurology, Children's Hospital of Philadelphia, University of Pennsylvania the Perelman School of Medicine, Philadelphia, Pennsylvania., Flickinger J; Department of Physical Therapy, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania., Jones JN; Department of Physical Therapy, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania., Kichula EA; Division of Neurology, Children's Hospital of Philadelphia, University of Pennsylvania the Perelman School of Medicine, Philadelphia, Pennsylvania.
Jazyk: angličtina
Zdroj: Pediatric neurology [Pediatr Neurol] 2021 May; Vol. 118, pp. 1-5. Date of Electronic Publication: 2021 Feb 05.
DOI: 10.1016/j.pediatrneurol.2021.01.012
Abstrakt: Background: Onasemnogene abeparvovec was recently approved for the treatment of spinal muscular atrophy (SMA) in children younger than two years; however, clinical trials were primarily completed in children younger than seven months, so practical experience dosing older children began in summer 2019. Here, we look at the safety and efficacy of onasemnogene in seven infants older than seven months who were treated at our center.
Methods: Seven patients were included.
Results: Acute viral symptoms with emesis and/or fever were seen in six of seven patients two to three days after the infusion. Thrombocytopenia occurred in four of seven patients, and six of seven patients had prolonged steroid courses due to persistently elevated liver enzymes, one of whom required escalation to intravenous steroids. All patients demonstrated motor improvements, which were apparent by three months, although with continued progress in those patients followed for longer periods of time.
Conclusions: Overall, onasemnogene appears to be efficacious in children older than seven months and well tolerated. Side effects were similar to those previously reported, although more common and in some cases more severe and more prolonged than seen in the original trials. The impact of age, weight, and other confounding factors on development of side effects still needs to be elucidated.
(Copyright © 2021 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: